- Home
- KNSA vs BXSL Comparison
KNSA vs BXSL Comparison
Compare KNSA & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | BXSL |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KNSA | BXSL |
|---|---|---|
| Price | $76.63 | $24.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $60.86 | $27.18 |
| AVG Volume (30 Days) | 428.4K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 12.87% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.27 | 0.15 |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $37.48 | N/A |
| Revenue Next Year | $17.87 | N/A |
| P/E Ratio | $290.81 | ★ $162.80 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $35.29 | $22.47 |
| 52 Week High | $82.94 | $28.82 |
Technical Indicators
Market Signals| Indicator | KNSA | BXSL |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 45.85 |
| Support Level | $44.95 | $24.17 |
| Resistance Level | $82.25 | $25.00 |
| Average True Range (ATR) | 2.37 | 0.39 |
| MACD | -0.80 | -0.09 |
| Stochastic Oscillator | 19.36 | 3.85 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.